Magnetic polymer particles

• US 4,335,094 A
• Filed: 01/26/1979
• Issued: 06/15/1982
• Est. Priority Date: 01/26/1979
• Status: Expired due to Term

• Current Assignee: Klaus H. Mosbach
• Original Assignee: Klaus H. Mosbach
• Inventors: Mosbach, Klaus H.
• Primary Examiner(s): Nucker, Christine M.
• Application Number:
  US06/021,603
• Time in Patent Office: 1,236 Days
• Field of Search: 424/1, 424/12, 424/9, 424/1.5, 23/230 B
• US Class Current: 424/1.37
• CPC Class Codes: A61K 9/5094 Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting
• CPC Class Codes: C12N 11/02 Enzymes or microbial cells immobilised on or in an organic carrier
• CPC Class Codes: C12N 11/14 Enzymes or microbial cells immobilised on or in an inorganic carrier
• CPC Class Codes: G01N 2400/32 Galactans, e.g. agar, agarose, agaropectin, carrageenan
• CPC Class Codes: G01N 2446/10 the magnetic material being used to coat a pre-existing polymer particle but not being present in the particle core
• CPC Class Codes: G01N 33/5434 using magnetic particle immunoreagent carriers which constitute new materials per se

Abstract

This invention relates to magnetic polymer particles as carriers of biologically, preferably pharmaceutically, active substances, the utilization of the magnetic polymer particles, the method of retaining a biologically active substance, preferably a pharmaceutically active substance within a restricted area, and the method of treating diseased tissue with the use of the magnetic polymer particles.

Claims

1. Magnetic polymer particles as carriers of biologically active substance comprising

particles of a polymer having a lattice or pores;

a biologically active substance associated with said polymer particles, and

magnetic material deposited in said lattice or pores wherein said magnetic material is deposited by contacting the polymer particles with a colloidal solution comprising said magnetic material.

3. Magnetic polymer particles as claimed in claim 1 or 2, wherein the biologically active substance is pharmaceutically active.

4. Magnetic polymer particles as claimed in claim 1 or 2, wherein the biologically active substance is selected from the group consisting of an enzyme inhibitor, an enzyme, a cytostaticum, a radio nucleotid, insulin, a steroid and a live microbe.

5. Magnetic polymer particles as claimed in claim 1 or 2 wherein the biologically active substance is a proteolytic enzyme.

6. Magnetic polymer particles as claimed in claim 1 or 2, wherein the polymer is porous.

7. Magnetic polymer particles as claimed in claim 1 or 2, wherein the polymer is biodegradable.

8. Magnetic polymer particles as claimed in claim 1 or 2, wherein the polymer is selected from the group consisting of an acrylic polymer, and a polysaccharide.

9. Magnetic polymer particles as claimed in claim 1 or 2, wherein the polymer is selected from the group consisting of agarose and starch.

10. Magnetic polymer particles as claimed in either of claims 1 or 2, wherein the magnetic material is colloidal.

11. Magnetic polymer particles as claimed in claim 9, wherein the magnetic material is colloidal ferrite.

2. Magnetic polymer particles as carriers of biologically active substance, comprising

particles of a polymer, which is derived from polymerizable monomers, said particles having a lattice or pores,

a biologically active substance associated with said polymer particles, and

magnetic material deposited in said lattice or pores, wherein said magnetic material is deposited by contacting the polymerizable monomers with a colloidal solution comprising said magnetic material.

12. A process for the production of magnetic polymer particles as carriers for biologically active substance comprising the step of contacting polymer particles having a lattice or pores, which particles carry the biologically active substance, with a colloidal solution of magnetic material, such that the magnetic material is deposited in the pores or lattice of said polymer particles.

17. The process according to claim 12, 13 or 14 wherein said colloidal solution contains a solvent and said process further comprises the step of removing solvent from said colloidal solution of magnetic material after said contacting step.

19. A process as claimed in any one of claims 12 to 16, wherein there is associated with the magnetic polymer particles as biologically active substance a pharmaceutically active substance.

20. A process as claimed in any one of claims 12 to 16, wherein there is associated with the magnetic polymer particles as biologically active substance a substance selected from the group consisting of an enzyme inhibitor, an enzyme, a cytostaticum, a radio nucleotid, insulin, a steroid and a live microbe.

21. A process as claimed in any one of claims 12 to 16, wherein there is associated with the magnetic polymer particles as biologically active substance a proteolytic enzyme.

22. A process as claimed in any one of claims 12 to 16, wherein as polymer particles use is made of porous polymer particles.

23. A process as claimed in any one of claims 12 to 16, wherein use is made of a biodegradable polymer.

24. A process as claimed in any one of claims 12 to 16, wherein as polymer particles use is made of particles selected from the group consisting of an acrylic polymer and a polysaccharide.

25. A process as claimed in any one of claims 12 to 16, wherein as polymer particles use is made of particles selected from the group consisting of agarose and starch.

27. A process as claimed in any one of claims 12 to 16, wherein colloidal ferrite is used as magnetic material.

13. A process for the production of magnetic polymer particles as carriers for biologically active substance comprising the step of contacting polymer particles having a lattice or pores with a colloidal solution of magnetic material and the biologically active substance, such that the magnetic material and the biologically active substance are deposited in the pores or lattice of said polymer particles.

14. A process for the production of magnetic polymer particles as carriers for biologically active substance comprising the steps of contacting polymer particles having a lattice or pores with a colloidal solution of magnetic material such that the magnetic material is deposited in the pores or lattice of said polymer particle, and associating the biologically active substance with the magnetic polymer particles.

15. A process for the production of magnetic polymer particles as carriers for biologically active substance comprising the steps of contacting polymerizable monomers in a colloidal solution of magnetic material and polymerizing said monomers, such that said magnetic material is deposited in pores or a lattice of the resulting polymer particles, and associating the biologically active substance with the magnetic polymer particles.

18. The process according to claim 15 or 16 wherein said colloidal solution contains a solvent and said process further comprises the step of removing solvent from said colloidal solution of magnetic material after said polymerization step.

26. A process as claimed in claim 15 or 16, wherein an acrylic monomer is inserted as polymerizable monomer.

16. A process for the production of magnetic polymer particles as carriers for biologically active substance comprising the steps of contacting polymerizable monomers in a colloidal solution of magnetic material and the biologically active substance and polymerizing said monomers, such that said magnetic material and the biologically active substance are deposited in pores or a lattice of the resulting polymer particles.

28. A method of retaining a biologically active substance within a restricted area, characterized in that the biologically active substance is associated with particles of a polymer, which particles are given magnetic properties by incorporation of a magnetic material in the form of a colloidal solution, whereupon a magnetic field is applied to the restricted area for retaining the magnetic polymer particles with the substance associated therewith.

29. A method of retaining a biologically active substance as described in claim 28, wherein the substance is pharmaceutically active.

30. A method of retaining a biologically active substance as described in claim 28, wherein the polymer is porous.

31. A method of retaining a biologically active substance as described in claim 28, wherein the polymer is biodegradable.

32. A method of retaining a biologically active substance as described in claim 28, wherein the polymer is selected from the group consisting of red corpuscles, particles of a liposome, an acrylic polymer and a polysaccharide.

33. A method of retaining a biologically active substance as described in claim 32, wherein said polymer is agarose or starch.

34. A method of treating a diseased tissue, characterized in that an effective amount of a pharmaceutically active substance is concentrated in the tissue by supply of the substance to the tissue associated with a carrier in the form of polymer particles, which have been given magnetic properties by incorporation of a magnetic material in the form of a colloidal solution, and that the magnetic carrier with the associated pharmaceutical substance is concentrated to the diseased tissue by the application of a magnetic field.

35. A method of treating a diseased tissue as described in claim 34, wherein the polymer is porous and/or biodegradable.

36. Magnetic starch particles as carriers of biologically active substance comprising

particles of starch having a lattice or pores;

a biologically active substance associated with said starch particles, and

magnetic material deposited in said lattice or pores wherein said magnetic material is deposited by contacting starch particles with a colloidal solution comprising saig magnetic material.

37. A method of retaining a biologically active substance within a restricted area, characterized in that the biologically active substance is associated with particles of starch, which particles are given magnetic properties by incorporation of a magnetic material in the form of a colloidal solution, whereupon a magnetic field is applied to the restricted area for retaining the magnetic starch particles with the substance associated therewith.

38. A method of treating a diseased tissue, characterized in that an effective amount of a pharmaceutically active substance is concentrated in the tissue by supply of the substance to the tissue associated with a carrier in the form of starch particles, which have been given magnetic properties by incorporation of a magnetic material in the form of a colloidal solution, and that the magnetic carrier with the associated pharmaceutical substance is concentrated to the diseased tissue by the application of a magnetic field.

39. A process for the production of magnetic starch particles as carriers for biologically active substance comprising the step of contacting starch particles having a lattice or pores, which particles carry the biologically active substance, with a colloidal solution of magnetic material, such that the magnetic material is deposited in the pores or lattice of said starch particles.